←Return to Faculty Page

John L. Johnson, M.D.

Professor of Medicine & Global Health and Diseases, Case Western Reserve University

Division of Infectious Diseases & HIV Medicine

Email : jlj@case.edu
Office Phone : 216.844.2646
Fax : 216.844.1632


  • B.S. : Biology, Gannon University, 1974-1977
  • M.D. : University of Pittsburgh School of Medicine, 1977-1981
  • Internship and Residency : Internal Medicine, Vanderbilt University, 1981-1985
  • Fellowship : Pulmonary Medicine, University Hospitals Case Medical Center, 1985-1987

Research Interests

Dr. Johnson's research interests have focused on phase 1, 2 and 3 IND and non-IND clinical trials of new drugs, immunotherapeutic agents and vaccines for the prevention and treatment of tuberculosis. Other areas of interest include HIV and TB interactions, immunopathogenesis of M. avium complex disease and tuberculosis, TB diagnostics, tuberculosis, HIV vaccines, surrogate markers of response to TB treatment, pulmonary infections in immunocompromised persons, and research capacity strengthening in developing countries. Dr. Johnson is the component leader for clinical trials trials for the TB Research Unit at CWRU and the Principal Investigator for tuberculosis clinical trials for Site 30 Kampala, Uganda of the CDC-sponsored Tuberculosis Trials Consortium (TBTC) network.

Selected References

  • Bark CM, Gitta P, Ogwang S, Nsereko M, Thiel BA, Eisenach KD, Boom WH, Joloba ML, Johnson JL. Comparison of time to positive and colony counting in an early bactericidal activity study of anti-tuberculosis treatment. Int J Tuberc Lung Dis 2013;11:1448-1451.
  • Johnson JL, Geldenhuys H, Thiel BA, Toefy A, Suliman S, Pienaar B, Chheng P, Scriba T, Boom WH, Hanekom W, Hatherill M. Effect of isoniazid therapy for latent TB infection on QuantiFERON-TB Gold In-tube responses in tuberculin skin test positive adults in a high TB incidence area: A controlled study. Chest 2014;145:612-617.
  • Mahapatra S, Hess AM, Johnson JL, Eisenach KD, DeGroote MA, Gitta P, Joloba ML, Kaplan G, Walzl G, Boom WH, Belisle JT. A metabolic biosignature of early response to anti-tuberculosis treatment. BMC Infect Dis 2014 Jan 31;14:53. doi: 10/1186/1471-2334-14-53.
  • Nahid P, Bliven-Sizemore E, Jarlsberg LG, De Groote MA, Johnson JL, Muzanyi G, Engle M, Weiner M, Janjic N, Sterling DG, Ochsner UA. Aptamer-based proteomic signature of intensive phase treatment response in pulmonary tuberculosis. Tuberculosis (Edinb) 2014; 94:187-196.
  • Hatherill M, Geldenhuys H, Pienaar B, de Kock M, Luabeya AKK, Tameris M, Suliman S, Chheng P, Debanne SM, Hoft DF, Boom WH, Hanekom W, Johnson JL. Safety and reactogenicity of BCG revaccination with isoniazid preclearance in TST positive adults. Vaccine 2014; 32:3982-3988.
  • Dorman EE, Savic RM, Goldberg S, Stout JE, Schluger N, Muzanyi G, Johnson JL, Nahid P, Hecker EJ, Heilig CM, Bozeman L, Feng PJI, Moro RN, MacKenzie W, Dooley KE, Nuermberger EL, Vernon A, Weiner M and the Tuberculosis Trials Consortium. Daily rifapentine for the treatment of pulmonary tuberculosis: a randomized, dose-ranging trial. Am J Respir Crit Care Med 2015;191;333-343.